145 related articles for article (PubMed ID: 15041742)
1. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.
Katano H; Pesnicak L; Cohen JI
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4960-5. PubMed ID: 15041742
[TBL] [Abstract][Full Text] [Related]
2. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
3. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.
Pioche-Durieu C; Keryer C; Souquère S; Bosq J; Faigle W; Loew D; Hirashima M; Nishi N; Middeldorp J; Busson P
J Virol; 2005 Nov; 79(21):13326-37. PubMed ID: 16227255
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts.
Picchio GR; Kobayashi R; Kirven M; Baird SM; Kipps TJ; Mosier DE
Cancer Res; 1992 May; 52(9):2468-77. PubMed ID: 1314693
[TBL] [Abstract][Full Text] [Related]
5. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
7. HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
Cohen JI
Br J Cancer; 2005 May; 92(9):1593-8. PubMed ID: 15856040
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
10. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
11. The extract of Chrysanthemum indicum Linne inhibits EBV LMP1-induced NF-κB activation and the viability of EBV-transformed lymphoblastoid cell lines.
Kim JE; Jun S; Song M; Kim JH; Song YJ
Food Chem Toxicol; 2012 May; 50(5):1524-8. PubMed ID: 22387267
[TBL] [Abstract][Full Text] [Related]
12. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
13. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
Sugimoto M; Tahara H; Ide T; Furuichi Y
Cancer Res; 2004 May; 64(10):3361-4. PubMed ID: 15150084
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus.
Baran-Marszak F; Laguillier C; Youlyouz I; Feuillard J; Mariette X; Fagard R; Raphaël M
Cytokine; 2006 Mar; 33(6):337-45. PubMed ID: 16713282
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-infected marmoset cells transfected with c-myc do not form lymphomas in mice with severe combined immunodeficiency.
Salimi B; O'Gorman MR; Variakojis D; Bendet M; Newman M; Poupko E; Katz BZ
Mol Genet Metab; 1998 Jul; 64(3):205-12. PubMed ID: 9719630
[TBL] [Abstract][Full Text] [Related]
16. Model of angiogenesis in mice with severe combined immunodeficiency (SCID) and xenoengrafted with Epstein-Barr virus-transformed B cells.
Woodford NL; Call DR; Remick DG; Rochford R
Comp Med; 2004 Apr; 54(2):209-15. PubMed ID: 15134368
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
18. The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB.
Nakamura H; Ishii C; Suehiro M; Iguchi A; Kuroda K; Shimizu K; Shimizu N; Imadome K; Yajima M; Fujiwara S
Virus Res; 2008 Feb; 131(2):170-9. PubMed ID: 17963943
[TBL] [Abstract][Full Text] [Related]
19. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression.
Mei YP; Zhu XF; Zhou JM; Huang H; Deng R; Zeng YX
Cancer Lett; 2006 Feb; 232(2):189-98. PubMed ID: 16458115
[TBL] [Abstract][Full Text] [Related]
20. EBV transformation overrides gene expression patterns of B cell differentiation stages.
Siemer D; Kurth J; Lang S; Lehnerdt G; Stanelle J; Küppers R
Mol Immunol; 2008 Jun; 45(11):3133-41. PubMed ID: 18430472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
